Tag: M.W:300-400

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

General procedure: 1H-NMR spectra were recorded on a DRX 400 (9.4 T, 400.13 MHz) spectrometer (Bruker Espanola S.A., Madrid, Spain) at 300 K. The [Host] values in the range of 1.02 to 1.85 ¡Á 10-3 correspond to a weighted quantity of host in 2 mL of CDCl3 (S33657, deuterium content >99.8%, water content <0.01%, containing silver wire as stabilizer, Merck S.L., Mollet del Valles-Barcelona, Spain). A given quantity of the guest (about 2 ¡Á 10-2 M) was weighed in a 1 mL volumetric flask and host solution was added to reach the graduation mark; in this way we know that the host concentration remains constant. Host and guest were weighted in a AE260-Delta Range scale (error ¡À 0.00005 g, Mettler Toledo, L' Hospitalet de Llobregat-Barcelona, Spain) and eVol XR hand-held automated analytical syringes (500 muL, 50 muL) from SGE Analytical Science (Trajan Scientific Europe Ltd, Crownhill, Milton Keynes, United Kingdom) previously calibrated for CDCl3, were used to perform additions. 1H-NMR titrations were used to quantify Ka values (see Figure 5 for two representative plots)., 10534-59-5

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Garcia, M. Angeles; Farrn, M. Angeles; Mara, Dolores Santa; Claramunt, Rosa M.; Torralba, M. Carmen; Torres, M. Rosario; Jaime, Carlors; Elguero, Jos; Molecules; vol. 20; 6; (2015); p. 9862 – 9878;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

(28A) tert-Butyl{3-[4-(3,4-dichlorobenzyloxy)phenyl]-3-vinyloxypropoxy}dimethylsilane3-(tert-Butyldimethylsilyloxy)-1-[4-(3,4-dichlorobenzyloxy)phenyl]propan-1-ol (300 mg, 0.680 mmol) produced in Example 27 (27B), palladium(II) trifluoroacetate (12 mg, 0.036 mmol), and 4,7-diphenyl-1,10-phenanthroline (12 mg, 0.036 mmol) were dissolved in butyl vinyl ether (5 mL), and triethylamine (20 muL, 0.14 mmol) was added thereto, and the resulting mixture was stirred under a nitrogen atmosphere at 80 C. for 4 hours. After cooling to room temperature, the reaction solution was filtered, and the solvent was distilled off under reduced pressure, whereby a crude product was obtained. This crude product was purified by silica gel column chromatography (hexane:ethyl acetate=100:0 to 96:4 (v/v)), whereby the objective title compound was obtained as a colorless oily substance (275 mg, yield: 87%).1H NMR (CDCl3, 400 MHz): delta0.04 (3H, s), 0.05 (3H, s), 0.91 (9H, s), 1.85 (1H, m), 2.07 (1H, m), 3.41 (1H, m), 3.57 (1H, m), 3.95 (1H, dd, J=1.6, 6.6 Hz), 4.23 (1H, dd, J=1.6, 14.1 Hz), 4.90 (1H, dd, J=5.1, 8.2 Hz), 5.00 (2H, s), 6.29 (1H, dd, J=6.6, 14.1 Hz), 6.92 (2H, d, J=9.0 Hz), 7.22 (2H, d, J=9.0 Hz), 7.24-7.28 (2H, m), 7.45 (1H, d, J=8.6 Hz), 7.54 (1H, d, J=2.0 Hz)

1662-01-7, 1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DAIICHI SANKYO COMPANY, LIMITED; US2011/53974; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1435-55-8, Hydroquinidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

From dihydroquinidine To a 0 C. solution of 1.22 g dihydroquinidine (0.0037 mol) in 30 mL of CH2 Cl2 was added 0.78 mL of Et3 N (0.0056 mol; 1.5 eq), followed by 0.71 mL of p-chlorobenzoyl chloride (0.005 mol; 1.2 eq) in 1 mL CH2 Cl2. After stirring 30 minutes at 0 C. and 1 hour at room temperature, the reaction was quenched by the addition of 10% Na2 CO3 (20 mL). After separation, the aqueous layer was extracted with three 10 mL portions of CH2 Cl2. The combined organic layers were dried over Na2 SO4 and the solvent removed under vacuum. The crude product was purified as described above. Dihydroquinidine p-chlorobenzoate (1) was obtained in 91% yield (1.5g) as a white foam., 1435-55-8

The synthetic route of 1435-55-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Massachusetts Institute of Technology; US4871855; (1989); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13104-56-8, 4′-(4-Methoxyphenyl)-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Accurately weighed Eu(TTA)2.4H2O 1.375 g, terpyridine (Tpy-OCH3) 0.658 g. Then added to a round-bottomed flask, completely dissolved in 50 ml of THF (tetrahydrofuran) and then warmed to 75 C. The reaction was heated for 3 hours under a magnetic stirrer. After the completion of the reaction, the solvent was removed, (TTA)2Tpy-OCH3 was prepared by vacuum drying at 60 C for 24 hours, and the calculated yield was weighed.

13104-56-8, As the paragraph descriping shows that 13104-56-8 is playing an increasingly important role.

Reference£º
Patent; Chongqing University Of Technology; Yang, Zhaolong; Liu, Shaojun; Zhang, Zhiming; Shang, Mingyong; Li, Chuan; Wang, Guoxia; Gao Bao; (10 pag.)CN104059093; (2016); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1119-97-7,MitMAB,as a common compound, the synthetic route is as follows.

General procedure: A 100mL round-bottom flask was equipped with a magnetic stir bar and a reflux condenser. To xylene (10.0mL), tetradecyltrimethylammonium bromide (1.1mmol) and a heterocyclic compound (1.0mmol) were added, followed bya solution of NaOH 50% (5.0 mL). The mixture was stirred at reflux temperature for 2-18 h. After completion of thereaction, the mixture was air-jet cooled to 25 C and TLC indicated the disappearance of the starting material. The reaction mix was treated with AcOEt (4 ¡Á 20 mL), and the organic phase separated and removed under reduced pressure. The residue was purified to analytical purity by column chromatography.

1119-97-7, The synthetic route of 1119-97-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Gonzalez-Gonzalez, Carlos A.; Vega, Juan Javier Mejia; Monroy, Ricardo Garcia; Gonzalez-Calderon, Davir; Corona-Becerril, David; Fuentes-Benites, Aydee; Mascarua, Joaquin Tamariz; Gonzalez-Romero, Carlos; Journal of Chemistry; vol. 2017; (2017);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

10534-59-5, General procedure: A solution of H6buea (200 mg, 0.45 mmol) dissolved in 4 mL of anhydrous DMA was treated with solid KH (55 mg, 1.36 mmol) and stirred until gas evolution ceased. Fe(OAc)2 (79 mg, 0.45 mmol) was added to the pale yellow solution, and stirring was continued for 30 min. The resulting amber filtrate was treated with [Bu4N][OAc] (140 mg, 0.45 mmol) and stirred for 2 h, resulting in the precipitation of a white solid (305 mg) that was filtered, washed twice with Et2O, and dried under vacuum. The white solid was stirred in CH3CN for 1 h and filtered to remove KOAc (105 mg, 96%). The light yellow filtrate was concentrated to half its original volume and the slow addition of Et2O resulted in the formation of a white solid, which was then filtered, washed with Et2O, and dried under vacuum to afford 150 mg (47%) of the desired salt. [Bu4N]2[Fe(II)H22iPr]2 was prepared following a similar procedure to that of [Bu4N]2[Fe(II)H3buea]2 with H52iPr (150 mg, 0.37 mmol), KH (45 mg, 1.12 mmol), Fe(OAc)2 (66 mg, 0.37 mmol), and [Bu4N][OAc] (113 mg, 0.37 mmol). The amount of KOAc obtained was 105 mg (96% for 3 equiv) and 100 mg (42%) of [Bu4N]2[FeIIH22iPr] was isolated. FTIR (Nujol, cm-1) nu(NH) 3332, nu(CO) 1661, 1590, 1561, 1520. Repeated attempts to obtain a satisfactory elemental analysis were unsuccessful.

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Lacy, David C.; Mukherjee, Jhumpa; Lucas, Robie L.; Day, Victor W.; Borovik; Polyhedron; vol. 52; (2013); p. 261 – 267;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

23616-79-7, N-Benzyl-N,N-dibutylbutan-1-aminium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Reference Example 82 A mixture of 3-[3-methoxy-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propionaldehyde (1.79 g), sodium cyanide (0.3 g), acetic anhydride (0.62 g), benzyltributylammonium chloride (0.79 g), water (12 ml) and dichloromethane (35 ml) was stirred for 15 hours at room temperature. The organic layer was separated, which was washed with water and dried (MgSO4), followed by distilling off the solvent. The resulting oily product was subjected to column chromatography on silica gel. From the fraction eluted with ethyl acetate-hexane (1:3, v/v), was obtained 2-acetoxy-4-[3-methoxy-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]butyronitrile (2.0 g, 94%), NMR(delta ppm in CDCl3): 2.14(3H,s), 2.12-2.31(2H,m), 2.41(3H,s), 2.78(2H,t,J=8 Hz), 3.87(3H,s), 5.04(2H,s), 5.27(1H,t,J=7 Hz), 6.70(1H,dd,J=8&2 Hz), 6.71(1H,d,J=2 Hz), 7.00(1H,d,J=9 Hz), 7.42-7.47(3H,m), 7.99-8.04(2H,m), 23616-79-7

23616-79-7 N-Benzyl-N,N-dibutylbutan-1-aminium chloride 159952, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Takeda Chemical Industries, Ltd.; US5932601; (1999); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25316-59-0,Benzyltributylammonium bromide,as a common compound, the synthetic route is as follows.

EXAMPLE 36 3,4-Dihydro-6-(4-hydroxyphenyl)-1-methylpyrrolo[1,2-a]pyrazine (5.0 g), 100 ml of methylene chloride, 5.3 ml of benzyl bromide and 0.8 g of benzyltributylammonium bromide was added in succession to a solution of 1.8 g of sodium hydroxide in 100 ml of water under argon. The mixture was boiled under reflux overnight and stirred and subsequently cooled. After the addition of 100 ml of methylene chloride and 100 ml of water the phases were separated and the aqueous phase was extracted twice with 100 ml of methylene chloride each time. The organic phases were combined, dried with MgSO4 and freed from solvent. The residue, 10.3 g of brown oil, was chromatographed on 500 g of silica gel with methylene chloride/methanol mixtures (99:1 to 9:1) as the eluent. The crude product, 4.9 g of brown, amorphous material, was dissolved in a 10-fold amount of hot ethanol and treated with 1.1 equivalents of a saturated solution of fumaric acid in ethanol. The product, 2.2 g of yellow crystals, was recrystallized from a 20-fold amount of ethanol. There were obtained 1.8 g (19%) of 6-[p-(benzyloxy)phenyl]-3,4-dihydro-1-methylpyrrolo[1,2-a]pyrazine fumarate (1:1); m.pt.: 165-168 C. (dec.).

25316-59-0, The synthetic route of 25316-59-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Hoffmann-La Roche Inc.; US5292732; (1994); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13104-56-8, 4′-(4-Methoxyphenyl)-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

13104-56-8, 4,4?-bipyridine (23mg, 0.15 mmol) and atpy (51 mg, 0.15 mmol) in CH2Cl2 was added to a solution of Cu(CH3COO)2¡¤H2O (30 mg, 0.15 mmol) in methanol (15 mL). After stirring for 10min, an excess of NH4PF6 (60 mg, 0.37 mmol) was added to solution. The reaction mixture was then stirred for 2 h. The solvent was removed at reduced pressure and the green residue was precipitated using diethyl ether. Yield: 32mg, 31%; m.p. 233-235 C (dec.). Anal. Calc. for C58H48Cu2F12N8O6P2¡¤1.5H2O. CH2Cl2: C, 47.72; H, 3.54; N, 7.42. Found: C, 47.26; H, 3.03; N, 7.99%. TGA-DTA: calc. by formula C58H48Cu2F12N8O6P2¡¤0.5H2O: H2O%=0.64, 2(CH3COO)%=8.44, 4,4?-bpy%=12.18, Cu(CH3COO)2%=16.18. Determined H2O%=0.71, 2(CH3COO)%=6.15, 4,4?-bpy%=12.81, Cu(CH3COO)2%=16.91. IR data (KBr, cm-1): 3389, 3055, 1598, 1470, 1407, 1243, 1189, 1019, 835, 794, 688, 641, 586, 519. Green crystals of 3 were obtained from a MeOH/diethyl ether solution.

The synthetic route of 13104-56-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Momeni, Badri Z.; Heydari, Sepideh; Polyhedron; vol. 97; (2015); p. 94 – 102;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

115754-62-6, ((1,3-Dioxolan-2-yl)methyl)tributylphosphonium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3,5-dibromobenzaldehyde (16.1 g, 61.0 mmol) was added to a cold (ice-water bath) solution of tert-butoxide (13.0 g, 116 mmol), (l,3-dioxolan-2-ylmethyl)tri-n-butylphosphine bromide salt (4.5 M, 32 cm3, 144 mmol) in 400 cm3 of ether under argon. The mixture was stirred at 0-2 C for 2 h. 1.0 M HCl(aq) (300 cm3) was added to the mixture. The reaction was gradually warmed to room temperature and stirred at room temperature for 21 h. The two layers were separated. The aqueous layer was extracted with ether (3 x 200 cm3). The organic layer and the ether extracts were combined, washed with brine (1 x 300 cm3) and dried over anhydrous magnesium sulfate. The solvents were completely removed to leave a yellow solid. The solid was purified by column chromatography of silica gel using ethyl acetate-light petroleum (40-60 C) as eluent to give 3.36 g (19%) of A-1 as a colourless solid; deltaH(200 MHz; CDCl3) 6.68 (1 H, dd, J1A & 16 Hz, vinylH), 7.33 (1 H, d, J16 Hz, vinylH), 7.33 (2 H, m, ArH), 7.63 (1 H, m, ArH), and 9.72 (1 H, d, J7.6 Hz, CHO); m/z [CI(NH3)] 306, 308, 310 (MNH4+), and 288, 290, 292 (M+)., 115754-62-6

The synthetic route of 115754-62-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ISIS INNOVATION LIMITED; THE UNIVERSITY COURT OF THE UNIVERSTIY OF ST ANDREWS; WO2004/20448; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI